A fluorescent immunochromatographic test strip for the detection of human α-Klotho protein, its preparation method and application

By designing a fluorescent immunochromatographic test strip and utilizing MSN-QD fluorescent microspheres coupled with antibodies, the issues of convenience and sensitivity in the detection of human α-Klotho protein have been resolved, achieving efficient and low-cost detection suitable for aging status assessment and early screening of related diseases.

CN123066331APending Publication Date: 2026-11-10DALIAN XIANGLONG LIFE TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611254247.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-18
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing technologies are difficult to detect human α-Klotho protein efficiently and conveniently, especially in prokaryotic or lower eukaryotic expression systems where expression efficiency is low, post-translational modifications are inconsistent, antibody specificity is insufficient, and existing detection methods are complex to operate and not suitable for large-scale screening and home applications.

Method used

A fluorescent immunochromatographic test strip was used, with MSN-QD fluorescent microspheres conjugated to human α-Klotho antibody and chicken IgY antibody, combined with a nitrocellulose membrane and absorbent pad, to achieve high sensitivity and quantitative detection of human α-Klotho protein.

Benefits of technology

It achieves highly sensitive, stable, and quantitative detection of human α-Klotho protein, suitable for non-invasive, portable, and low-cost detection, and applicable to aging status assessment and early screening of related diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123066331A_ABST
    Figure CN123066331A_ABST
Patent Text Reader

Abstract

This invention discloses a fluorescent immunochromatographic test strip for the detection of human α-Klotho protein and its application, belonging to the field of biomolecular detection technology. The test strip of this invention includes a backing, on which a sample pad, a fluorescent binding pad, a chromatography membrane coated with detection lines and control lines, and an absorbent pad are sequentially arranged. The preparation method of the fluorescent immunochromatographic test strip of this invention includes steps such as labeling antibodies with fluorescent microspheres, spraying the binding pad, coating the chromatography membrane, and assembling the test strip. The overall structure is simple, the preparation process is convenient, and it is suitable for rapid quantitative detection of human α-Klotho protein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biomolecular detection technology, specifically relating to a fluorescent immunochromatographic test strip for the detection of human α-Klotho protein, its preparation method, and its application. Background Technology

[0002] Current research on aging detection mainly focuses on molecular biomarkers that can reflect the decline of physiological functions and homeostasis imbalances. Cell cycle inhibitors (such as p16), inflammation and stress-related factors (such as GDF15), and molecules involved in metabolic and endocrine regulation are all used to assess aging status. Among the many candidate biomarkers, human α-Klotho protein has attracted widespread attention due to its well-defined anti-aging biological functions and its close association with age-related diseases.

[0003] Klotho protein is a glycoprotein with significant anti-aging functions, first discovered in a mouse model carrying a homozygous attenuated Klotho gene (kl / kl). This model exhibits a multi-system accelerated aging phenotype. Studies have shown that in humans, Klotho protein levels gradually decline with age, and are significantly reduced in patients with age-related diseases such as chronic kidney disease, diabetes, and Alzheimer's disease. Furthermore, its low expression is closely associated with increased all-cause mortality. Animal experiments have further confirmed that Klotho deficiency can induce the activation of age-associated secretory phenotypes (SASPs) in the kidneys and multiple tissues, accelerating abnormalities in age-related signaling pathways at the mechanistic level, thereby accelerating the overall aging process. Clinically, Klotho protein levels in both blood and urine show a decreasing trend with age. Blood Klotho is the most widely used detection method, as it best reflects the overall Klotho level and systemic aging status. Urine Klotho, as a non-invasive indicator derived from the kidneys, directly reflects the expression level of renal Klotho, offering unique advantages in kidney function assessment and aging status monitoring. The above studies show that Klotho protein has the dual properties of being an aging regulator and a biomarker of aging status, which can provide important biological evidence for early screening, risk assessment and monitoring of intervention effects of aging-related diseases.

[0004] Structurally, the intracellular region of human α-Klotho protein contains only 11 amino acids, the transmembrane region contains approximately 21 amino acids, and the extracellular region is as long as 980 amino acids, including two highly homologous repeating domains, KL1 (approximately 450 amino acids) and KL2 (approximately 430 amino acids). In the kidneys and choroid plexus of the brain, transmembrane Klotho can be cleaved by proteases to generate approximately 130 kDa of soluble human α-Klotho, which is released into the bloodstream and cerebrospinal fluid, and dominates in the body in its secretory form.

[0005] However, the research and detection applications of human α-Klotho protein still face multiple technical bottlenecks: First, the full-length human α-Klotho protein contains a transmembrane domain, is highly hydrophobic, and the human gene has a high GC content and contains rare codons, making it prone to translational arrest, protein truncation, or misfolding in prokaryotic or lower eukaryotic expression systems, resulting in low expression efficiency and solubility; Second, existing expression systems struggle to achieve post-translational modifications consistent with the human source, with prokaryotic systems lacking N-glycosylation capabilities and yeast systems exhibiting predominantly high-mannose glycosylation, significantly affecting protein stability, biological activity, and immunological properties; Third, existing human α-Klotho antibodies generally suffer from insufficient specificity, limited sensitivity, and low affinity, making it difficult to meet the needs of clinical detection and high-precision analysis.

[0006] Currently, serum or urine biomarkers such as human α-Klotho are mainly detected using immunological methods such as ELISA. Their detection performance is highly dependent on antibody quality, and the procedures are relatively complex, making them unsuitable for large-scale screening and home applications. Meanwhile, mainstream aging assessment technologies such as DNA methylation analysis, telomere length detection, and inflammatory factor detection, while possessing high accuracy, generally rely on invasive sampling and complex instrument operation, hindering their widespread application in primary healthcare and home settings.

[0007] Lateral flow immunochromatography (LFIA) is widely used in infectious disease screening and home health monitoring due to its advantages such as ease of operation, rapid detection, and no need for large instruments. Traditional LFIA often uses colloidal gold as a signal label, but its sensitivity and quantitative ability are limited. In recent years, fluorescent microspheres and upconversion nanomaterials have improved detection performance to some extent, but they suffer from drawbacks such as high cost and complex preparation. In contrast, quantum dots (QDs) have advantages such as high quantum yield, broad excitation and narrow emission, and strong resistance to photobleaching, which can significantly improve the detection sensitivity and quantitative ability of LFIA, raising the detection limit from the μg / mL level to the pg / mL level, making them particularly suitable for the detection of low-abundance biomarkers.

[0008] Therefore, there is an urgent need to develop a non-invasive, portable, low-cost, and quantitative detection technology to meet the practical needs of human α-Klotho protein detection, rapid assessment of aging status, and daily health management. Summary of the Invention

[0009] Therefore, the purpose of this invention is to provide a fluorescent immunochromatographic test strip for the detection of human α-Klotho protein, its preparation method, and its application.

[0010] To achieve the above objectives, the present invention provides the following technical solution: In a first aspect, the present invention provides a fluorescent immunochromatographic test strip for the detection of human α-Klotho protein. The test strip includes a backing and a sample pad, a fluorescent binding pad, a chromatography membrane, and an absorbent pad on the backing, with each part overlapping in sequence. The sample pad is provided with a sample application well. The fluorescent binding pad contains the antibody fluorescent markers MSN-QD-human α-Klotho antibody 1 and MSN-QD-chicken IgY antibody. The chromatography membrane is a nitrocellulose membrane, on which a detection line and a control line are provided. The detection line is coated with human α-Klotho antibody 2, and the control line is coated with goat anti-chicken antibody.

[0011] Based on the above technical solution, further, the MSN-QD-human α-Klotho antibody 1 is composed of MSN-QD fluorescent microspheres conjugated with human α-Klotho antibody 1; the MSN-QD-chicken IgY antibody is composed of MSN-QD fluorescent microspheres conjugated with chicken IgY antibody; the MSN-QD fluorescent microspheres are prepared by mixing and compositing thiol-based mesoporous silica spheres with CdSe / CdS / ZnS core-shell quantum dots, followed by hydrophobic modification, phase transfer, and washing purification.

[0012] Based on the above technical solution, the human α-Klotho antibody 1 further comprises an antibody heavy chain variable region and a light chain variable region selected from any of the following groups: (1) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2; (2) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.3; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.4.

[0013] SEQ ID NO.1: QLQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGIGGTNYNEKFKAKATLTADKSSSTAYMQLSSLTSDDSAVYFCARESYYGNYGAMDYWGQGTLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK SEQ ID NO.2: DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIYAASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPLTFGAGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC SEQ ID NO.3: EVQLQQSGPGLVAPSQSLSITCTVSGFSLSLYGVHWVRQPPGKGLEWLGVIWAGGTTDYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCARDDYGILDYWGQGT LVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGC KPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTIS KTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK SEQ ID NO.4: DILMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGGGTKLEIK RADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC Based on the above technical solution, the human α-Klotho antibody 2 further comprises an antibody heavy chain variable region and a light chain variable region selected from any of the following groups: (1) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.5; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.6; (2) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.7; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.8.

[0014] SEQ ID NO.5: QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGIGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARERALTGTYHAMDYWGQGTLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK SEQ ID NO.6: DIVMTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIYAASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPYTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC SEQ ID NO.7: QVQLQQSGAELVKPGASVKLSCKASGYTFTSYWMHWVKLRPGQGFEWIGEINPGNGGTKYNENFKRKATLTVDKSSSTAYLQLSSSLTSEDSAVYYCTIERDYGFAYWGQG TLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCG CKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTI SKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK SEQ ID NO.8: DILMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPYTFGGGTKLEIK RADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC Based on the above technical solution, the width of the test strip is further 2~4 mm.

[0015] Based on the above technical solution, further, one side of the fluorescent binding pad is adjacent to the sample pad, and the other side overlaps with the chromatography membrane, with an overlap length of 1~3mm.

[0016] Based on the above technical solution, the overlap length between the absorbent pad and the chromatography membrane is further 0.5~1.5mm.

[0017] Secondly, the present invention provides a method for preparing the aforementioned fluorescent immunochromatographic test strip, characterized by comprising the following steps: (1) Preparation of antibody fluorescent markers: MSN-QD fluorescent microspheres were coupled with human α-Klotho antibody 1 and chicken IgY antibody respectively, blocked, centrifuged and washed and resuspended to obtain fluorescent marker conjugates; (2) Spraying the bonding pad: The fluorescent marker compound is uniformly sprayed onto the bonding pad material and dried to obtain the fluorescent bonding pad; the drying temperature is 35~39℃; (3) Coating the chromatographic membrane: Spray 1~3 mg / mL of the human α-Klotho antibody 2 onto the detection line of the chromatographic membrane, and spray 0.5~1.5 mg / mL of goat anti-chicken polyclonal antibody onto the quality control line of the chromatographic membrane; the drying temperature after spraying is 35~39℃; (4) Assemble the human α-Klotho protein test strip: The sample pad, the fluorescent binding pad, the chromatography membrane and the absorbent pad are sequentially overlapped and pasted on the backing, and the test strip is cut.

[0018] Thirdly, the present invention provides the application of the fluorescent immunochromatographic test strip in the preparation of a kit for the specific detection of human α-Klotho protein.

[0019] Based on the above technical solution, the test sample of the kit is urine or blood.

[0020] Based on the above technical solution, furthermore, a fluorescence detection device is used to read the fluorescence signal intensity of the detection line and the control line in the test strip. By using the signal ratio and combining it with a pre-established standard curve, the quantitative analysis of the human α-Klotho protein content in the sample can be achieved.

[0021] Compared with the prior art, the present invention has the following beneficial effects: 1. The diagnostic test strips or kits for human α-Klotho target-related diseases prepared by this invention have broad clinical application prospects in the early screening, accurate diagnosis and targeted therapy of diseases such as anti-aging, chronic kidney disease, diabetes, and Alzheimer's disease, and can provide patients with safer and more effective diagnostic and treatment options.

[0022] 2. The fluorescent flow-measuring immunochromatographic test strip based on quantum dot-mesoporous silica prepared in this invention can achieve highly sensitive, stable, quantitative, and rapid detection of human α-Klotho protein, providing an innovative solution for convenient assessment of human aging status and early screening of related diseases.

[0023] 3. The MSN-QD fluorescent composite probe prepared in this invention loads quantum dots (QDs) inside mesoporous silica nanoparticles (MSNs). Through the spatial confinement effect, it effectively reduces the interference of the external environment on the quantum dots, suppresses fluorescence quenching, and achieves high loading of quantum dots, thereby enhancing the overall fluorescence signal and further reducing the detection limit. This effectively overcomes the problems of fluorescence quenching and poor environmental stability that quantum dots are prone to in practical applications. Attached Figure Description

[0024] To more clearly illustrate the embodiments of the present invention, the accompanying drawings involved in the embodiments will be briefly described below.

[0025] Figure 1 This is a schematic diagram illustrating the assembly and detection process of the fluorescent immunochromatographic test strip prepared according to the present invention.

[0026] Figure 2 The images shown are transmission electron microscope (TEM) scans from Example 1 of the present invention, where (a) is a QD TEM image, (b) is an MSN TEM image, (c) is an MSN-QD TEM image, (d) is an MSN-QD-human α-Klotho antibody 1 TEM image, (e) is an MSN scanning electron microscope (SEM) image, and (f) is an MSN-QD SEM image.

[0027] Figure 3 This is a potential diagram of MSN, MSN-QD, MSN-QD-COOH and MSN-QD-human α-Klotho antibody 1 in Example 1 of the present invention.

[0028] Figure 4 This is the sensitivity test result of the immunochromatographic test strip for the inventor's α-Klotho protein standard, where 0 represents the PBS control group.

[0029] Figure 5 The results of this invention for detecting α-Klotho protein in human blood samples. Detailed Implementation

[0030] The present invention will be described in detail below with reference to the embodiments. However, the implementation of the present invention is not limited thereto. Obviously, the embodiments described below are only some embodiments of the present invention. For those skilled in the art, other similar embodiments can be obtained without creative effort and all fall within the protection scope of the present invention.

[0031] Example 1: Preparation of MSN-QD fluorescent composite probe (1) Synthesis of mercapto-based mesoporous silica spheres (MSN-SH) 816 mg of triethanolamine was added to 300 mL of ultrapure water, followed by 4.56 g of hexadecyltrimethylammonium bromide and 3.226 g of sodium salicylate. 48 mL of an ethanol solution of tetraethyl orthosilicate was slowly added dropwise under stirring. After the reaction was complete, the mixture was cooled to room temperature, centrifuged, and the precipitate was washed three times with ethanol to remove residual reactants. The MSN-SH microspheres were then collected.

[0032] (2) Preparation of quantum dots (QDs) The explosive nucleation of CdSe nuclei was achieved by high-temperature hot injection, followed by epitaxial growth of CdS and ZnS shells on the nuclei via continuous ion layer adsorption reaction (SILAR), which effectively passivated surface defects and improved fluorescence quantum yield and stability.

[0033] (3) Preparation of quantum dot MSN-QD fluorescent composite probe loaded on mesoporous silica microspheres 5 mL of MSN-SH ethanol solution was mixed with 1 mL of quantum dot chloroform dispersion (MSN-SH to quantum dots mass ratio 1:2). After the reaction, the composite material was collected by centrifugation and washed with chloroform to remove unbound quantum dots. Subsequently, OTMS was added to hydrophobically modify the surface of the composite material, forming a homogeneous organic phase dispersion system. Further ultrasonic treatment in a methanol / ammonia mixture was performed to transfer the material from the organic phase to the aqueous phase. Unreacted silane reagents were removed by repeated washing with methanol to obtain the MSN-QD fluorescent composite probe. Loading quantum dots (QDs) inside mesoporous silica nanoparticles (MSN) effectively reduces interference from the external environment on the quantum dots through spatial confinement, suppresses fluorescence quenching, and achieves high quantum dot loading, thereby enhancing the overall fluorescence signal and further reducing the detection limit.

[0034] Example 2: Preparation of MSN-QD-human α-Klotho antibody-1 immunoprobe Carboxylated MSN-QD (2 wt%) prepared in Example 1 was placed in MES buffer (0.1 M, pH=6.0), followed by the addition of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and N. Hydroxysuccinimide (NHS) was used to activate the microspheres. The activated particles were washed with water and redispersed in an equal volume of MES buffer (0.1 M, pH 6.5, containing 0.05% Tween 20). Chicken IgY antibody and human α-Klotho antibody 1 were then added separately, and the mixture was incubated with gentle shaking at 25°C. The antibody-labeled MSN-QD-human α-Klotho antibody 1 and MSN-QD-chicken IgY antibody were collected by centrifugation and redispersed in phosphate-buffered saline (PBS, 20 mM, pH 8.0, containing 2.5% BSA, 1% sucrose, and 2% PEG-2000) to form a storage dispersion (0.2 wt%).

[0035] Human α-Klotho antibody 1 contains a heavy chain variable region and a light chain variable region selected from any of the following groups: (1) For detecting α-Klotho protein in human urine: the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2; SEQ ID NO.1: QLQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGIGGTNYNEKFKAKATLTADKSSSTAYMQLSSLTSDDSAVYFCARESYYGNYGAMDYW GQGTLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRD CGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKT ISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK SEQ ID NO.2: DIVLTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIYAASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPLTFGAGTKLE IKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (2) For detecting α-Klotho protein in human blood: the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.3; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.4.

[0036] SEQ ID NO.3: EVQLQQSGPGLVAPSQSLSITCTVSGFSLSLYGVHWVRQPPGKGLEWLGVIWAGGTTDYNSALMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCARDDYGILDYWGQGTLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK SEQ ID NO.4: DILMTQSQKFMSTSVGDRVSVTCKASQNVGTNVAWYQQKPGQSPKALIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNSYPLTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC Example 3: Assembly of human α-Klotho protein test strip First, the sample pads and conjugate pads were pretreated by using 20 mM phosphate buffer (pH=7.4, containing 1% BSA, 2.5% sucrose, 1% Tween 20, and 0.3% PVPK30) and drying at 37 °C for 3 hours. Then, human α-Klotho antibody 2 (2 mg / mL) and goat anti-chicken polyclonal antibody (1 mg / mL) were applied to a nitrocellulose membrane, respectively. Human α-Klotho antibody 2 was used as the capture antibody paired with human α-Klotho antibody 1. The antibody was streaked onto the detection and control lines of the nitrocellulose membrane at a speed of 1.5 μL / cm, 300 mm length, and 70 mm / s, respectively; drying parameters were 37 °C for 12–16 h. The MSN-QD-human α-Klotho antibody 1 and MSN-QD-chicken IgY antibody dispersion (0.2 wt%) prepared in Example 2 were added to a centrifuge tube and thoroughly mixed. This mixture was then sprayed onto the pretreated conjugate pads and dried to obtain conjugate pads containing the antibody mixture. The mixture was homogenized using a vortex mixer, and then sprayed using a decoction gold sprayer at a speed of 10 μL / cm, a length of 300 mm, and a speed of 60 cm / min. The drying temperature was 37℃, and the drying time was 2–6 h.

[0037] Human α-Klotho antibody 2 contains a heavy chain variable region and a light chain variable region selected from any of the following groups: (1) For detecting α-Klotho protein in human urine: the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.5; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.6; SEQ ID NO.5: QVQLQQSGAELVRPGTSVKVSCKASGYAFTNYLIEWVKQRPGQGLEWIGVINPGIGGTNYNEKFKGKATLTADKSSSTAYMQLSSLTSDDSAVYFCARERALTGTYHAMDY WGQGTLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRD CGCKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKT ISKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK SEQ ID NO.6: DIVMTQSPASLAVSLGQRATISCRASESVDNYGISFMNWFQQKPGQPPKLLIYAASNQGSGVPARFSGSGSGTDFSLNIHPMEEDDTAMYFCQQSKEVPYTFGGGTKLE IKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (2) For detecting α-Klotho protein in human blood: the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.7; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.8.

[0038] SEQ ID NO.7: QVQLQQSGAELVKPGASVKLSCKASGYTFTSYWMHWVKLRPGQGFEWIGEINPGNGGTKYNENFKRKATLTVDKSSSTAYLQLSSSLTSEDSAVYYCTIERDYGFAYWGQG TLVTVSAAKTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEPVTVTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVPSSTWPSETVTCNVAHPASSTKVDKKIVPRDCG CKPCICTVPEVSSVFIFPPKPKDVLTITLTPKVTCVVVDISKDDPEVQFSWFVDDVEVHTAQTQPREEQFNSTFRSSVSELPIMHQDWLNGKEFKCRVNSAAFPAPIEKTI SKTKGRPKAPQVYTIPPPKEQMAKDKVSLTCMITDFFPEDITVEWQWNGQPAENYKNTQPIMDTDGSYFVYSKLNVQKSNWEAGNTFTCSVLHEGLHNHHTEKSLSHSPGK SEQ ID NO.8: DILMTQSHKFMSTSVGDRVSITCKASQDVGTAVAWYQQKPGQSPKLLIYWASTRHTGVPDRFTGSGSGTDFTLTISNVQSEDLADYFCQQYSSYPYTFGGGTKLEIK RADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC The absorbent pad, nitrocellulose membrane, treated conjugation pad, and sample pad are adhered to a plastic backing to assemble the test strip, which is then cut into 3mm wide strips. The test strip product is stored at room temperature to dry. Figure 1 As shown, the sample pad, conjugation pad, nitrocellulose membrane, and absorbent pad are sequentially stacked and bonded to a PVC base plate. The absorbent pad's end is approximately 1 mm from the edge of the coated nitrocellulose membrane, with the overlap between the two controlled to approximately 2 mm. The conjugation pad faces upwards, with one side overlapping the nitrocellulose membrane by approximately 2 mm, and the other side adjacent to the sample pad. The sample pad is placed flush against the edge of the release paper below it.

[0039] Example 4: Detection of α-Klotho in human urine Human α-Klotho protein standard (concentration 0.5 mg / mL) was diluted with PBS buffer to 100 ng / mL, 64 ng / mL, 32 ng / mL, 16 ng / mL, 8 ng / mL, 4 ng / mL, 2 ng / mL, 1 ng / mL, and 0.5 ng / mL, respectively. Twenty test strips from the same batch were used to test their sensitivity, with 0 serving as the PBS control group. Before testing, the samples were equilibrated to room temperature. Using a pipette, 100 μL of each dilution was slowly and vertically added to the sample pad of the test strip prepared in Example 3. The test results were observed after 15 minutes. The results are as follows: Figure 4 As shown, the results indicate that the detection limit is 0.5 ng / mL, which is within the range of human α-Klotho protein content in the human body.

[0040] The collected urine samples were diluted with sample diluent (0.01 M PBS, pH 7.4) at a volume ratio of 1:5 and used directly for detection. 100 μL of the diluted urine sample was added to the sample well of the test strip sample pad. The strip was incubated at room temperature for 15 minutes, and the fluorescence intensity values ​​of the T and C lines were read using a fluorescence immunoassay analyzer. The T / C ratio was then used as the basis for analysis. Figure 4 The standard curve equation was plotted, and the concentration of α-Klotho in human urine was calculated.

[0041] Example 5: Detection of α-Klotho in human blood Human α-Klotho protein standard (concentration 0.5 mg / mL) was diluted to 32 ng / mL, 16 ng / mL, 8 ng / mL, 4 ng / mL, 2 ng / mL, 1 ng / mL, 0.5 ng / mL, and 0.25 ng / mL using PBS buffer. Twenty test strips from the same batch were used to test their sensitivity, with 0 representing the PBS control group. Before testing, the samples were equilibrated to room temperature. 100 μL of each dilution was slowly and vertically added to the sample pad of the test strip prepared in Example 3 using a pipette. The test results were observed after 15 minutes, and a standard curve was plotted.

[0042] Collected blood samples were diluted with sample diluent (0.01 M PBS, pH 7.4) at a volume ratio of 1:5 and used directly for testing. 100 μL of the diluted blood sample was added to the sample well of the test strip sample pad and incubated at room temperature for 15 minutes. The fluorescence intensity values ​​of the T and C lines were then read using a fluorescence immunoassay analyzer. The T / C ratio was substituted into the standard curve equation to calculate the α-Klotho concentration in human blood. The sample detection results are shown below. Figure 5 As shown.

[0043] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A fluorescent immunochromatographic test strip for the detection of human α-Klotho protein, characterized in that, The test strip includes a backing and a sample pad, a fluorescent binding pad, a chromatography membrane, and an absorbent pad on the backing, with each part overlapping in sequence; the sample pad has a sample application well; the fluorescent binding pad contains the antibody fluorescent markers MSN-QD-human α-Klotho antibody 1 and MSN-QD-chicken IgY antibody; the chromatography membrane is a nitrocellulose membrane with a detection line and a control line; the detection line is coated with human α-Klotho antibody 2; the control line is coated with goat anti-chicken antibody; The MSN-QD-human α-Klotho antibody 1 is composed of MSN-QD fluorescent microspheres conjugated with human α-Klotho antibody 1; the MSN-QD-chicken IgY antibody is composed of MSN-QD fluorescent microspheres conjugated with chicken IgY antibody; the MSN-QD fluorescent microspheres are prepared by hydrophobic modification, phase transfer and washing purification of a mixture of thiol-based mesoporous silica spheres and CdSe / CdS / ZnS core-shell quantum dots.

2. The fluorescent immunochromatographic test strip according to claim 1, characterized in that, The human α-Klotho antibody 1 comprises a heavy chain variable region and a light chain variable region selected from any of the following groups: (1) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2; (2) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.3; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.

4.

3. The fluorescent immunochromatographic test strip according to claim 1, characterized in that, The human α-Klotho antibody 2 comprises a heavy chain variable region and a light chain variable region selected from any of the following groups: (1) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.5; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.6; (2) The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.7; the amino acid sequence of the light chain variable region is shown in SEQ ID NO.

8.

4. The fluorescent immunochromatographic test strip according to claim 1, characterized in that, The width of the test strip is 2-4 mm.

5. The fluorescent immunochromatographic test strip according to claim 1, characterized in that, The fluorescent binding pad is adjacent to the sample pad on one side and overlaps with the chromatography membrane on the other side, with an overlap length of 1~3 mm.

6. The fluorescent immunochromatographic test strip according to claim 1, characterized in that, The overlap length between the absorbent pad and the chromatography membrane is 0.5~1.5 mm.

7. A method for preparing a fluorescent immunochromatographic test strip according to any one of claims 1 to 6, characterized in that, Includes the following steps: (1) Preparation of antibody fluorescent markers: MSN-QD fluorescent microspheres were coupled with human α-Klotho antibody 1 and chicken IgY antibody as described in claim 2, respectively, blocked, centrifuged and washed and resuspended to obtain fluorescent marker conjugates; (2) Spraying the bonding pad: The fluorescent marker compound is uniformly sprayed onto the bonding pad material and dried to obtain the fluorescent bonding pad; the drying temperature is 35~39℃; (3) Coating the chromatographic membrane: Spray 1~3 mg / mL of the human α-Klotho antibody 2 described in claim 3 onto the detection line of the chromatographic membrane, and spray 0.5~1.5 mg / mL of goat anti-chicken polyclonal antibody onto the control line of the chromatographic membrane; the drying temperature after spraying is 35~39℃; (4) Assemble the human α-Klotho protein test strip: The sample pad, the fluorescent binding pad, the chromatography membrane and the absorbent pad are sequentially overlapped and pasted on the backing, and the test strip is cut.

8. The use of the fluorescent immunochromatographic test strip according to any one of claims 1 to 6 in the preparation of a kit for the specific detection of human α-Klotho protein.

9. The application according to claim 8, characterized in that, The test sample for the kit is urine or blood.

10. The application according to claim 8, characterized in that, The fluorescence signal intensity of the test line and control line in the test strip is read using a fluorescence detection device. The signal ratio is used in conjunction with a pre-established standard curve to achieve quantitative analysis of the human α-Klotho protein content in the sample.